Skip to main content

Tumor Necrosis Factor- α

A Promising Therapeutic Target for Asthma?

BioDrugs volume 21, pages 345–349 (2007)Cite this article

Abstract

Asthma is a disease that encompasses a variety of features including airway smooth muscle abnormalities, airway inflammation, and structural changes in the airway. Historically, it has been classified depending on the severity of the disease, the frequency of symptoms, and the level of treatment required to control them. Severe or refractory asthma accounts for approximately 10% of the patient population with asthma and for about 30% of the healthcare costs of this disease. It is often associated with conditions that might lead to activation of innate immunity in the lung, and it has been suggested that some of the features of severe asthma might be due to upregulation of the tumor necrosis factor-α (TNFα) pathway. In support of this, studies have shown that severe asthma is associated with an increased presence of TNFα within the airway and an increase in TNFα expression on peripheral blood mononuclear cells. Moreover, TNFα has the ability to induce several of the proinflammatory changes associated with severe asthma. Interest in the role of TNFα in severe asthma has increased following reports that antagonism with etanercept or infliximab is associated with improvement in asthma control in patients with severe asthma. In this article, we discuss the biology, function, and clinical effects of TNFα with particular reference to severe asthma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Geneva: NHLBI/WHO, 1995

  2. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: i1–94

    Google Scholar 

  3. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117 (3): 496–506

    Article  PubMed  CAS  Google Scholar 

  4. Tulic MK, Hamid Q. New insights into the pathophysiology of the small airways in asthma. Clin Chest Med 2006; 27 (1): 41–52, vi

    Article  PubMed  Google Scholar 

  5. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160 (3): 1001–8

    PubMed  CAS  Google Scholar 

  6. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22 (3): 470–7

    Article  Google Scholar 

  7. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000; 106 (6): 1033–42

    Article  PubMed  CAS  Google Scholar 

  8. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23 (5): 723–9

    Article  PubMed  CAS  Google Scholar 

  9. Wenzel SE. Severe asthma in adults. Exp Lung Res 2005; 31 Suppl. 1: 22

    PubMed  Google Scholar 

  10. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365 (9463): 974–6

    Article  PubMed  Google Scholar 

  11. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3 (10): 831–44

    Article  PubMed  CAS  Google Scholar 

  12. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354 (7): 697–708

    Article  PubMed  CAS  Google Scholar 

  13. Bodey KJ, Semper AE, Redington AE, et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 1999; 54 (10): 1083–93

    Article  PubMed  CAS  Google Scholar 

  14. Wilson SJ, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164 (6): 1047–52

    PubMed  CAS  Google Scholar 

  15. Churg A, Dai J, Tai H, et al. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002; 166 (6): 849–54

    Article  PubMed  Google Scholar 

  16. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95 (5): 2409–15

    Article  PubMed  CAS  Google Scholar 

  17. O’Malley WE, Achinstein B, Shear MJ. Journal of the National Cancer Institute, Vol. 29, 1962: action of bacterial polysaccharide on tumors: II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. Nutr Rev 1988; 46 (11): 389–91

    Article  PubMed  Google Scholar 

  18. Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005; 109 (2): 135–42

    Article  CAS  Google Scholar 

  19. Eigler A, Sinha B, Hartmann G, et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18 (10): 487–92

    Article  PubMed  CAS  Google Scholar 

  20. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997; 91 (1): 31–9

    Article  PubMed  CAS  Google Scholar 

  21. Tracey KJ. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog Clin Biol Res 1998; 397: 335–43

    PubMed  CAS  Google Scholar 

  22. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370 (6486): 218–20

    Article  PubMed  CAS  Google Scholar 

  23. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 2000; 9 (3): 497–514

    Article  PubMed  CAS  Google Scholar 

  24. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174 (7): 753–62

    Article  PubMed  CAS  Google Scholar 

  25. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344 (12): 907–16

    Article  PubMed  CAS  Google Scholar 

  26. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126 (2): 402–13

    Article  PubMed  CAS  Google Scholar 

  27. Evereklioglu C. Managing the symptoms of Behcet’s disease. Expert Opin Pharmacother 2004; 5 (2): 317–28

    Article  PubMed  CAS  Google Scholar 

  28. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50 (7): 2264–72

    Article  PubMed  CAS  Google Scholar 

  29. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60 (12): 1012–8

    Article  PubMed  CAS  Google Scholar 

  30. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53 (1): 45–53

    Article  PubMed  CAS  Google Scholar 

  31. Zheng Y, Saftig P, Hartmann D, et al. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004; 279 (41): 42898–906

    Article  PubMed  CAS  Google Scholar 

  32. Davis JM, Narachi MA, Alton NK, et al. Structure of human tumor necrosis factor alpha derived from recombinant DNA. Biochemistry 1987; 26 (5): 1322–6

    Article  PubMed  CAS  Google Scholar 

  33. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262 (15): 6951–4

    PubMed  CAS  Google Scholar 

  34. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990; 87 (8): 3127–31

    Article  PubMed  CAS  Google Scholar 

  35. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336 (15): 1066–71

    Article  PubMed  CAS  Google Scholar 

  36. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10 (5): 471–80

    PubMed  CAS  Google Scholar 

  37. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57 (9): 774–8

    Article  PubMed  CAS  Google Scholar 

  38. vanOverveld FJ, Jorens PG, Rampart M, et al. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clin Exp Allergy 1991; 21 (6): 711–4

    Article  PubMed  Google Scholar 

  39. Coward WR, Okayama Y, Sagara H, et al. NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002; 169 (9): 5287–93

    PubMed  Google Scholar 

  40. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152 (1): 76–80

    PubMed  CAS  Google Scholar 

  41. Renzetti LM, Paciorek PM, Tannu SA, et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996; 278 (2): 847–53

    PubMed  CAS  Google Scholar 

  42. Amrani Y, Martinet N, Bronner C. Potentiation by tumour necrosis factor-alpha of calcium signals induced by bradykinin and carbachol in human tracheal smooth muscle cells. Br J Pharmacol 1995; 114 (1): 4–5

    Article  PubMed  CAS  Google Scholar 

  43. Amrani Y, Panettieri Jr RA, Frossard N, et al. Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1996; 15 (1): 55–63

    PubMed  CAS  Google Scholar 

  44. Nakatani Y, Nishimura Y, Nishiuma T, et al. Tumor necrosis factor-alpha augments contraction and cytosolic Ca (2+) sensitivity through phospholipase A (2) in bovine tracheal smooth muscle. Eur J Pharmacol 2000; 392 (3): 175–82

    Article  PubMed  CAS  Google Scholar 

  45. Parris JR, Cobban HJ, Littlejohn AF, et al. Tumour necrosis factor-alpha activates a calcium sensitization pathway in guinea-pig bronchial smooth muscle. J Physiol 1999; 518 (Pt 2): 561–9

    Article  PubMed  CAS  Google Scholar 

  46. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002; 14 (6): 477–92

    Article  PubMed  CAS  Google Scholar 

  47. Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84 (8): 2834–9

    Article  PubMed  CAS  Google Scholar 

  48. Sullivan DE, Ferris M, Pociask D, et al. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005; 32 (4): 342–9

    Article  PubMed  CAS  Google Scholar 

  49. Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122 (1): 103–11

    Article  PubMed  CAS  Google Scholar 

  50. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168 (11): 1308–11

    Article  PubMed  Google Scholar 

  51. Michel O, Ginanni R, Duchateau J, et al. Domestic endotoxin exposure and clinical severity of asthma. Clin Exp Allergy 1991; 21 (4): 441–8

    Article  PubMed  CAS  Google Scholar 

  52. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med 2004; 169 (8): 963–8

    Article  PubMed  Google Scholar 

  53. Bruce C, Thomas PS. The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005; 205 (2): 126–32

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Enrico Heffler is the recipient of a European Respiratory Society/European Lung Foundation Fellowship, number 327.

The European Respiratory Society/European Lung Foundation had no role in the preparation of the manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Allergy and Clinical Immunology, University of Torino, Turin, Italy

    Enrico Heffler

  2. ASO Ordine Mauriziano ‘Umberto I’, Turin, Italy

    Enrico Heffler

  3. Institute for Lung Health, University Hospital of Leicester National Health Service Trust, Glenfield Hospital, Leicester, UK

    Enrico Heffler &  Ian D. Pavord

  4. Division of Medical Sciences, University of Birmingham, Birmingham, UK

    Mike Berry

Authors
  1. Enrico Heffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mike Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian D. Pavord
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian D. Pavord.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Heffler, E., Berry, M. & Pavord, I.D. Tumor Necrosis Factor- α. BioDrugs 21, 345–349 (2007). https://doi.org/10.2165/00063030-200721060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721060-00002

Keywords

  • Asthma
  • Infliximab
  • Etanercept
  • Adalimumab
  • Severe Asthma